Medical Oncology最新文献

{"title":"Signaling pathways as the pivotal regulators of cisplatin resistance in tumor cells through SOX2 upregulation.","authors":"Negin Taghehchian, Iman Akhlaghipour, Amir Sadra Zangouei, Mahsa Palizkaran Yazdi, Meysam Moghbeli","doi":"10.1007/s12032-025-03004-9","DOIUrl":"10.1007/s12032-025-03004-9","url":null,"abstract":"<p><p>Chemotherapy is one of the first-line treatment options in cancer patients. Cisplatin (CDDP) is widely used as one of the antineoplastic agents in many cancers. Nevertheless, CDDP resistance is considered as a therapeutic challenge in cancer. Considering the CDDP side effects in normal tissues, prediction of CDDP response helps to select a suitable therapeutic strategy in cancer patients. Sex-determining region Y-box 2 (SOX2) is a critical regulator of tumor growth and embryogenesis that is involved in tumor metastasis, apoptosis, and cell proliferation, through association with other developmental/oncogenic signaling pathways. SOX2 has also a crucial role in CDDP resistance in tumor cells. Therefore, we discussed the role of SOX2 in regulation of CDDP response in tumor cells. It has been reported that SOX2 upregulation through PI3K/AKT, WNT, Hippo, and TGF-β signaling pathways mainly promotes the CDDP resistance in tumor cells. The present review can be an effective step in introducing SOX2 as a prognostic marker as well as a therapeutic target in cancer patients.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 10","pages":"437"},"PeriodicalIF":3.5,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circ_0000847 promotes the migration, invasion, and EMT process in colorectal cancer through binding to IGF2BP2 to enhance IGF2 mRNA stability.","authors":"Aikang Zhang, Yongbin Zheng","doi":"10.1007/s12032-025-02877-0","DOIUrl":"10.1007/s12032-025-02877-0","url":null,"abstract":"<p><p>Colorectal cancer (CRC) stands as one of the most prevalent forms of malignant gastrointestinal tumors. Circular RNAs (circRNAs) could serve as promising targets for therapeutic intervention in CRC. This study aims to uncover the significance and influence of circRNAs within the landscape of CRC. CircRNA microarray, RNase R assay, and fluorescence in situ hybridization were conducted to verify the expression and characteristics of circRNA. The biological behaviors of CRC cells were evaluated by cell counting kit-8, transwell assay, and wound-healing assay. The underlying mechanism was revealed using quantitative real-time PCR, Western bot, silver staining assay, biotin-labeled RNA pulldown, and RNA immunoprecipitation. The results indicated that circ_0000847, a CRC-associated circRNA, was over-expressed in CRC. Inhibition of circ_0000847 effectively restrained the migratory and invasive behaviors of CRC cells, alongside suppressing their epithelial-mesenchymal transition (EMT). Circ_0000847 bound to IGF2BP2, thereby enhancing the IGF2 mRNA stability. Importantly, overexpression of IGF2 abrogated the inhibitory effect of circ_0000847 depletion on CRC cellular processes. In addition, circ_0000847 promoted tumor growth in vivo. In summary, by engaging with IGF2BP2, circ_0000847 plays a role in stabilizing IGF2 mRNA, which in turn curtails the advancement of CRC. Hence, circ_0000847 could serve as an innovative and potentially pivotal target for the development of CRC therapies.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 10","pages":"436"},"PeriodicalIF":3.5,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanistic insights into the therapeutic potential of β-elemene on glioma and other central nervous system diseases.","authors":"Xiaoyu Wang, Lin Lin, Yu Cheng, Yongjie Wang","doi":"10.1007/s12032-025-03009-4","DOIUrl":"10.1007/s12032-025-03009-4","url":null,"abstract":"<p><p>The central nervous system (CNS) governs critical physiological processes, and its dysregulation drives severe pathologies, particularly glioma, a life-threatening malignancy with limited therapeutic options. β-elemene (ELE), the bioactive compound derived from Curcuma wenyujin, exhibits potent anti-glioma activity as both a monotherapy and in synergy with chemo- or radiotherapy. Beyond glioma, ELE demonstrates therapeutic versatility across CNS disorders, including traumatic brain injury, ischemic stroke, spinal cord injury, neuropathic pain, experimental autoimmune encephalomyelitis, and obesity-associated microbiota-gut-brain axis dysfunction. Mechanistically, modulation of key signaling pathways implicated in neoplastic proliferation, metastasis, neuroinflammation, apoptosis, and oxidative stress positions ELE as a promising candidate for repurposing traditional medicine in modern neurotherapeutics. This review synthesizes ELE's therapeutic efficacy, elucidates the underlying molecular mechanisms, and highlights outstanding questions to guide future research for ELE therapies, advocating for integrating traditional Chinese medicine-driven approaches into modern pharmacological innovation with favorable treatment outcomes.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 10","pages":"438"},"PeriodicalIF":3.5,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genistein enhances TLR3-mediated apoptosis and immune signaling in breast cancer cells.","authors":"Suleyman Kaleli, Asuman Deveci Ozkan, Gamze Guney Eskiler, Kaan Furkan Hamarat, Rabia Rana Derlioglu, Sevinc Yanar, Ecir Ali Cakmak","doi":"10.1007/s12032-025-02856-5","DOIUrl":"10.1007/s12032-025-02856-5","url":null,"abstract":"<p><p>Breast cancer is one of the most common malignant tumors globally and the second leading cause of cancer-related death in women. Toll-like receptors (TLR) constitute a family of transmembrane receptors playing a crucial role in innate immunity. TLR3 is a type of TLR that is activated following Poly (I:C) double-stranded RNA binding. TLR3 activation leads to tumor suppression, and TLR3 directly causes apoptotic effects in cancer cells. Genistein (GEN), a phytoestrogen found in soy, inhibits cellular proliferation, induces apoptosis, and arrests the cell cycle. Therefore, it is important to determine the roles of immunotherapeutic agents targeting TLR3 in cancer treatment. The study aimed to determine the anti-inflammatory effect of GEN on breast cancer cells for the first time. The anti-inflammatory effects of GEN on the TLR3 signaling pathway were evaluated using Annexin V and cell cycle analysis, immunofluorescence assay, acridine orange staining, Western blotting, and ELISA cytokine release level in MCF-7 (hormone-dependent) and MDA-MB-231 (triple negative) breast cancer cells. The GEN alone treatment increased apoptosis, cell cycle arrest, apoptotic cell morphology, and the expression of TLR3, IRF3, AP-1, and p-NF-kB proteins. Additionally, higher levels of INF-β and TNF-α in both cells compared to treatment with Poly I:C alone were detected. These effects were more pronounced in MCF-7 cells than in MDA-MB-231 cells. Stimulation of the TLR3 signaling pathway was enhanced in the presence of GEN, leading to increased apoptosis.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 10","pages":"435"},"PeriodicalIF":3.5,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of Tinospora cordifolia in breast cancer therapy.","authors":"Kadri Altundag","doi":"10.1007/s12032-025-03016-5","DOIUrl":"10.1007/s12032-025-03016-5","url":null,"abstract":"","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 10","pages":"433"},"PeriodicalIF":3.5,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolutionary conservation and cancer implications of the WNT signaling pathway.","authors":"Devesh Prajapati, Gayatri Ambere, Dyandevi Mathure, Dipanjan Karati, Dileep Kumar","doi":"10.1007/s12032-025-02950-8","DOIUrl":"10.1007/s12032-025-02950-8","url":null,"abstract":"<p><p>One of the essential cellular machinations co-opted by the WNT signaling pathway, including its canonical β-Catenin and non-canonical WNT/PCP and WNT/ Ca²⁺ sub-pathways, are events such as apoptosis, cancer cell metabolism, inflammation, and proliferation of cancer cells. This review article discusses, in detail, the molecular mechanism of action of the WNT signaling pathway and its components, and digression into evolutionary conservation, but focuses on WNT signaling in development and cancer biology. It also discusses WNT signaling components and the potential role in colorectal cancer (CRC) targeted therapy. The emphasis of the review is on the potential of bioactive compounds, Flavonoids, including Curcumin and Resveratrol, to block WNT signaling and present an opportunity for CRC therapy. It highlights new and existing inhibitors that modulate the WNT pathway, and describes the mechanisms and the evidence for clinical efficacy of these drugs and compounds. This review also provides a comprehensive analysis and talks about ground-breaking discoveries of WNT pathway components and their novel roles in cancer stemness, metastasis, and immune surveillance. As such, this article described the progress toward accumulating evidence of targeting the WNT pathway, describing the clinical trials targeting PORCN inhibitors, FZD antagonists, and inhibitors of β-Catenin transcriptional activity, making it a thorough search of the WNT signaling pathway in cancer that provides potential therapeutic opportunities.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 10","pages":"434"},"PeriodicalIF":3.5,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral microbiome alterations after cancer treatment: a scoping review and analysis.","authors":"Francis A Boksa, Leah I Leinbach, Drashty P Mody, Sukirth M Ganesan, Jacqueline W Mays","doi":"10.1007/s12032-025-02998-6","DOIUrl":"10.1007/s12032-025-02998-6","url":null,"abstract":"<p><p>Cancer therapies impact the oral cavity. Oral microbial changes occur following cancer therapy, but the nature, duration, and implications of these shifts are not well understood. Exposure to radiation, chemotherapy or cellular therapies has been associated with oral microbiome shifts toward dysbiosis and increased frequency of pathogenic species in the microbiome. Despite these findings, much remains unknown about cancer-therapy-related changes in the oral microbiome following specific therapies, and what the associated long-term oral health implications may be for cancer survivorship. We therefore conducted a scoping review of oral microbiome studies in patients undergoing cancer therapy to broadly synthesize the literature on the oral microbiome in the context of cancer therapy, categorize findings, and identify research gaps to inform future projects. This scoping review of the literature describes substantial changes in the oral microbiome during cancer treatment, specifically chemotherapy, radiation therapy, and stem cell transplantation. Across 62 studies, chemotherapy, radiation therapy, and stem cell transplantation were associated with substantial changes in oral microbial communities. Among studies that assessed alpha diversity, the richness of species that comprised the oral microbiome often increased, encompassing more microbial taxa, while the evenness of species decreased, suggesting that community change was dominated by a few species. Frequently observed changes included decreases in commensal taxa such as Streptococcus and Prevotella and increases in opportunistic organisms such as Candida albicans and Staphylococcus aureus. While mucositis was often studied, consistent microbial predictors of this outcome were not identified The present study lays the groundwork for future research on the unique oral microenvironment and health needs in cancer survivors. The alterations in microbiome composition associated with specific cancer treatment categories add to our limited understanding of the key role of cancer therapy modalities on the oral microbiome.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 10","pages":"432"},"PeriodicalIF":3.5,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12364993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcoming the blood-brain barrier (BBB) in pediatric CNS tumors: immunotherapy and nanomedicine-driven strategies.","authors":"Ali M Alaseem, Jihad Awadallah Alrehaili","doi":"10.1007/s12032-025-02984-y","DOIUrl":"10.1007/s12032-025-02984-y","url":null,"abstract":"<p><p>Pediatric central nervous system (CNS) tumors rank second among the fatal childhood malignancies, primarily due to the significant challenge posed by the blood-brain barrier (BBB), which limits the therapeutic delivery and contributes to poor clinical outcomes. This challenge is exacerbated by the distinct developmental traits of pediatric BBB, the immunosuppressive tumor microenvironment (TME), and the inherent diversity of different tumor types such as medulloblastoma and diffuse intrinsic pontine glioma (DIPG). Recent advances at the crossroad of immunotherapy and nanomedicine are paving the way for transformative strategies to penetrate the BBB and modify the immunogenic landscape within pediatric CNS tumors. Various nanoparticle-based approaches such as liposomes and polymeric nanoparticles to exosomes have been engineered with surface ligands like transferrin and lactoferrin to improve the BBB targeting in pediatric CNS tumors. Moreover, stimuli-responsive nanocarriers, such as pH- and enzyme-sensitive paradigms, are being implemented to enhance controlled drug release in the acidic and protease-rich TME. Additional, synergistic therapies that combine chemotherapeutics, immune checkpoint inhibitors, oncolytic viruses, and cancer vaccines are being adapted for pediatric patients, with enhanced drug delivery aided by nanocarrier formulations have led to significant tumor regression and prolonged survival in animal models. Additionally, tailored treatments utilizing genetic and pharmacokinetic biomarkers, along with innovative BBB-on-chip platforms, enable precise targeting and real-time monitoring of drug permeability across the barrier. In this review, we have emphasized that how a deeper understanding of pediatric BBB biology, targeted modulation of the barrier, and innovative nanotechnology-immunotherapy combinations is providing newer treatment modalities and less toxic therapies for children with CNS tumors.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 10","pages":"431"},"PeriodicalIF":3.5,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticancer efficacy of nerolidol, cyclophosphamide, and their combination against breast cancer cell line MCF-7.","authors":"Md Tousif, Masood Nadeem, Ms Tabassum, M Moshahid Alam Rizvi, Syed Ehtaishamul Haque","doi":"10.1007/s12032-025-02997-7","DOIUrl":"10.1007/s12032-025-02997-7","url":null,"abstract":"<p><p>In cancer, chemotherapeutic agents like cyclophosphamide (CP), is the most frequently used drug but the side effects caused by it, limits it's application. Therefore, creation of anticancer medicines with high efficacy and no or minimum side effects is a priority. In recent times, research on natural bioactive has been increased since they are efficient, safe, and economical. We earlier proved that Nerolidol (NER), a naturally derived sesquiterpene alcohol is a natural bioactive compound that could significantly reduce the CP-induced organ toxicities in Swiss albino mice. Thus, in this study, we intended to evaluate the anti-cancer property of NER alone and its potentiating effect in combination with CP in Michigan Cancer Foundation-7 (MCF-7) breast cancer cell line. MCF-7 is one of the most extensively used human breast cancer cell line, primarily because it closely resembles estrogen receptor-positive (ER⁺), luminal-type breast cancer, which accounts for a significant proportion (~ 70%) of clinical breast cancer cases. MCF-7 cells are also non-invasive and less aggressive, which makes them suitable for early-stage tumor modelling and cytotoxicity screening. It provides a well-characterized and clinically relevant model for evaluating the efficacy of anticancer agents. MTT assay, clonogenic assay, cytotoxicity, wound healing assay, and cell cycle arrest was assessed to determine the anticancer properties of NER, CP, and their combination against MCF-7 cells. The change in nuclear morphology was determined by 4', 6-diamidino-2- phenylindole (DAPI) to assess apoptosis. The NER, CP, and their combination at IC₅₀ concentration was found to be cytotoxic against MCF-7 cells, inhibited colony formation, migration of MCF-7 cells and arrested the cell cycle at G0/G1, G2/M, and S phase, respectively. Thus, NER, CP, and their combination showed anticancer property against MCF-7 cells, when administered alone or in combination, but the combination treatment proved to be the best.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 10","pages":"430"},"PeriodicalIF":3.5,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: Auraptene-induced cytotoxic effects in acute myeloid leukemia cell lines.","authors":"Majid Ghorbani, Mohammad Soukhtanloo, Amir Salek Farrokhi, Seyed Mahdi Hassanian, Fatemeh Ghorbani, Amir Reza Afshari, Mohsen Taherian, Mohammad Hadi Sadeghian","doi":"10.1007/s12032-025-02990-0","DOIUrl":"10.1007/s12032-025-02990-0","url":null,"abstract":"","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 10","pages":"429"},"PeriodicalIF":3.5,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}